Table 2.
Clinical course records of GEP-NEN patients
| Treatments PRIOR to tissue sampling | Tissue collection | Treatments AFTER tissue sampling | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample ID | Clinical course 1 | Clinical course 2 | Clinical course 3 | Clinical course 4 | Clinical course 5 | Clinical course 6 | Clinical course 7 | Clinical course A | Clinical course B | Clinical course C | |
| C8802 | Cisplatin & Etoposidea (PR) | FOLFOX (Mixed response) | FOLFIRI (Mixed response) | Irinotecan & Carboplatin (Discont. due to AE) | CAPTEM & Bevacizumab (PD) | Surgery primary tumor | |||||
| C3301 | Surgery primary tumor | Cisplatin & Etoposide (PR) | Doxorubicin & Cyclophosphamide (PR) | Resection liver metastasis | Brachytherapy | ||||||
| C5501 | Cisplatin & Etoposide (SD) | FOLFIRINOX | CAPTEM (PD) | Debulking | CAPTEM & Bevacizumab (PD) | Debulking | CAPTEM & Bevacizumab (PD) | ||||
| C0701 | Streptozotocin/5-FU (SD) | CAPTEM (PD) | FOLFOX (PR) | FOLFIRI (PR) | Resection liver metastasis | Carboplatin & Etoposid (PD) | |||||
| C9502 | Surgery primary tumor | PRRT (PR) | Resection liver metastasis | PRRT & Temozolomideb (PR) | SSA | Resection liver metastasis | |||||
| C8101 | Cisplatin & Etoposidea (PR) | Carboplatin & Etoposide (PR) | FOLFIRI (PD) | Topotecan (Discont. due to AE) | Best supportive care | Resection liver metastasis & SIRT | FOLFOX & RTX (PD) | ||||
| aP321 | Streptozotocin & Doxorubicin (SD; Delayed PR) | Surgery primary tumor | Streptozotocine & Doxorubicin (PR) | PRRT (PR) | SSA | PRRT (PR) | SSA | Resection liver metastasis | CAPTEMc (PR) | TAE | FOLFOX (PR) |
| aP490 | Surgery primary tumor & liver metastases | Cisplatin & Etoposide (PD) | CAPTEM (PD) | Best supportive care | |||||||
PR partial response, SD stable disease, PD progressive disease.
aStable and long-lasting response.
bTemozolomide discontinued due to bone marrow toxicity.
cComplete response in peritoneal-, pleural-, and cutaneous metastasis; stable hepatic lesions.